A Principal Open-label Study to Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease

Trial Profile

A Principal Open-label Study to Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Flutemetamol-F-18 (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Diagnostic use; Registrational
  • Sponsors GE Healthcare
  • Most Recent Events

    • 20 Jul 2017 Results of post hoc analysis assessing additive effect of including other biomarkers in estimating risk of conversion to probable Alzheimers Disease presented at the Alzheimer's Association International Conference 2017
    • 10 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Jul 2014 Results published in a GE Healthcare Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top